Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | hypothetical protein, conserved | 0.0029 | 0.0309 | 0.0309 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0069 | 0.5826 | 0.5 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.0069 | 0.5826 | 1 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0069 | 0.5826 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0069 | 0.5826 | 0.5826 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0069 | 0.5826 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 1 | 1 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0069 | 0.5826 | 0.5 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0069 | 0.5826 | 1 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0069 | 0.5826 | 0.5826 |
Wolbachia endosymbiont of Brugia malayi | ribonuclease HI | 0.0027 | 0 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0069 | 0.5826 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0069 | 0.5826 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0029 | 0.0309 | 0.0309 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0069 | 0.5826 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0029 | 0.0309 | 0.0309 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.0029 | 0.0309 | 0.0309 |
Onchocerca volvulus | Ribonuclease H1 homolog | 0.0027 | 0 | 0.5 |
Echinococcus granulosus | proteasome prosome macropain | 0.0069 | 0.5826 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0029 | 0.0309 | 0.0309 |
Treponema pallidum | ribonuclease H (rnhA) | 0.0027 | 0 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0069 | 0.5826 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0069 | 0.5826 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0069 | 0.5826 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0069 | 0.5826 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0069 | 0.5826 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0069 | 0.5826 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 130 uM | Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells | ChEMBL. | 9154976 |
CC50 (functional) | = 130 uM | Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells | ChEMBL. | 9154976 |
EC50 (binding) | = 1.5 uM | Reverse transcriptase activity was measured in the culture supernatant, concentration that reduces by 50% the HIV produced in the supernatant. | ChEMBL. | 9154976 |
EC50 (binding) | = 1.5 uM | Reverse transcriptase activity was measured in the culture supernatant, concentration that reduces by 50% the HIV produced in the supernatant. | ChEMBL. | 9154976 |
EC50 (functional) | = 5 uM | Inhibition of HIV-1 LA1 cytopathic effects on CEM-CL13 cells in vitro. | ChEMBL. | 9154976 |
Ratio (functional) | = 26 | Ratio of CC50 in CEM-CL13 cells to EC50 in HIV-1 LA1 infected CEM-CL13 cells. | ChEMBL. | 9154976 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.